重组人干扰素α2b阴道泡腾片治疗宫颈高危型HPV感染的疗效分析范文.docVIP

WORD格式.可编辑 技术资料.整理分享 重组人干扰素α2b阴道泡腾片治疗宫颈高危型HPV感染的疗效分析 　　[摘要] 目的 探讨重组人干扰素α2b阴道泡腾片治疗宫颈高危型人乳头瘤病毒（HPV）感染的临床疗效。方法 方便选取2016年6月―2017年4月该院收治的115例宫颈高危型HPV感染患者为研究对象，依据治疗方法不同分为实验组（重组人干扰素α2b 阴道泡腾片，58例）和对照组（定期随访观察不做处理，57例）。疗程结束后，统计2组HPV转阴率，观察实验组用药不良反应。结果 实验组HPV总转阴率（68.97%）明显高于对照组（21.05%），差异有统计学意义（P0.05），患者用药无明显不适，不良反应率0.00%。 结论 重组人干扰素α2b 阴道泡腾片治疗宫颈高危型HPV感染疗效良好且无明显副作用，应用安全，值得推广。 　　[关键词] 高危HPV感染；宫颈粘膜慢性炎；宫颈上皮内瘤变1级；重组人干扰素α2b 阴道泡腾片 　　[中图分类号] R711 [文献标识码] A [文章编号] 1674-0742（2017）11（c）-0140-03 　　[Abstract] Objective This paper tries to investigate the clinical effect of recombinant human interferon α2b vaginal effervescence tablet in the treatment of high risk human papillomavirus （HPV） infection. Methods 115 cases of cervical high-risk HPV infection patients from June 2016 to April 2017 were convenient selected and divided into the experimental group （recombinant human interferon α2b vaginal effervescent tablets， 58 cases） and the control group （regular follow-up， 57 cases）， after the treatment， the HPV negative rate and adverse reaction of the two groups were compared. Results The total negative rate of HPV in the experimental group was 68.97%， significantly higher than that in the control group of 21.05%， the difference was statistically significant（P0.05）， the patients had no obvious discomfort， and the adverse reaction rate was 0.00%. Conclusion Recombinant human interferon α2b vaginal effervescent tablets in the treatment of cervical high-risk HPV infection has good curative effect and no obvious side effects. It is safe and worthy to be popularized. 　　[Key words] High-risk HPV infection； Cervical mucosa chronic inflammation； Cervical intraepithelial neoplasia 1； Recombinant human interferon α2b vaginal effervescent tablets 　　HPV为乳多空病毒科乳头瘤空泡病毒A属球形DNA病毒，具有传染性，多见于皮肤及女性生殖道，可引起多种疾病，人群感染率高[1]。目前，临床分离出的HPV有130余种，依据致病力大小可分为低危和高危两种类型，其中HPV-16、18等粘膜高危型HPV致癌危险性高，是临床研究普遍证实的